(19)
(11) EP 3 288 578 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
29.03.2023 Bulletin 2023/13

(45) Mention of the grant of the patent:
15.03.2023 Bulletin 2023/11

(21) Application number: 16721609.2

(22) Date of filing: 29.04.2016
(51) International Patent Classification (IPC): 
A61K 38/10(2006.01)
C07K 7/54(2006.01)
 A61K 38/12(2006.01)
C07K 7/64(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 38/00; A61K 9/0031; C07K 7/08; A61P 1/10; A61P 35/00; A61K 38/10; A61K 38/12
(86) International application number:
PCT/US2016/030061
(87) International publication number:
WO 2016/178979 (10.11.2016 Gazette 2016/45)

(54)

COMPOSITIONS FOR COLON CLEANSING AND THE TREATMENT OF GASTROINTESTINAL DISORDERS

ZUSAMMENSETZUNGEN ZUR DICKDARMREINIGUNG UND BEHANDLUNG VON GASTROINTESTINALEN STÖRUNGEN

COMPOSITION POUR LE NETTOYAGE DU CÔLON ET LE TRAITEMENT DE TROUBLES GASTRO-INTESTINAUX

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 01.05.2015 US 201562156077 P

(43) Date of publication of application:
07.03.2018 Bulletin 2018/10

(73) Proprietor: Ironwood Pharmaceuticals, Inc.
Boston, MA 02110 (US)

(72) Inventors:
  • CURRIE, Mark, G.
    Boston, MA 02129 (US)
  • SOLINGA, Robert
    Brookline, MA 02445 (US)
  • LEITHEISER, Christopher
    Arlington, MA 02474 (US)

(74) Representative: Mathys & Squire 
The Shard 32 London Bridge Street
London SE1 9SG
London SE1 9SG (GB)


(56) References cited: : 
WO-A1-2016/015055
 WO-A2-2014/131024
   
  • MOHAMMED AKHTER HOSSAIN ET AL: "Solid phase synthesis and structural analysis of novel A-chain dicarba analogs of human relaxin-3 (INSL7) that exhibit full biological activity", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 7, no. 8, 1 April 2009 (2009-04-01), pages 1547-1553, XP055082660, ISSN: 1477-0520, DOI: 10.1039/b821882j
  • GIOVANNI PITARI: "Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis", DRUG DESIGN, DEVELOPMENT AND THERAPY, 19 April 2013 (2013-04-19), pages 351-360, XP055148568, DOI: 10.2147/DDDT.S32252
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).